Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine
Phase I Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H2N2 (A/Ann Arbor/6/60 ca Recombinant), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H2N2 Infection in the Event of a Pandemic
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
H2N2 influenza viruses emerged in the 1950s replacing the then circulating H1N1 human influenza virus. The first cases occurred in China in 1956, and disease became widespread in 1956-1957, resulting in the "Asian Influenza" pandemic that was responsible for between 1 and 4 million deaths worldwide. H2N2 viruses have not circulated since 1968, when they were replaced by H3N2 influenza viruses and the resurgence of H1N1 viruses. For this reason, a large proportion of the population is now susceptible to infection with H2N2 influenza. If this subtype re-emerges, it could potentially cause the next pandemic. This vaccine, therefore, is an important priority in the development of vaccines against potential pandemic influenza strains.
This vaccine trial will be conducted in the Center for Immunization Research isolation unit in the Mason F. Lord Building at the Johns Hopkins Bayview Medical Center (Baltimore, MD). The study will be initiated between April 1st and December 20th, 2008, when wild-type influenza is unlikely to be circulating in the Baltimore area.
An individual's participation in the study will last approximately 90 days. All participants will receive two vaccinations approximately 4 - 8 weeks apart. After each vaccination, participants will remain in isolation at the study site for at least nine days or until rRT-PCR assays for influenza are negative for 2 consecutive days. A physical examination and nasal wash will occur each day during the isolation period. Blood collection will occur in isolation beginning on Day 7 until release. Follow-up outpatient visits are scheduled on Days 28 and 56 after the first vaccination and on Day 28 after the second vaccination. Follow-up visits will include serum collection, nasal wash, and interim medical history.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21205
- Johns Hopkins Bayview Medical Center, CIR Unit at the Mason F Lord Building
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- General good health
- Available for the duration of the trial
- If female, agree to use effective birth control methods for the duration of the study. More information on this criterion can be found in the protocol.
Exclusion Criteria:
- Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease. More information on this criterion can be found in the protocol.
- Behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, intereferes with the study
- Previous receipt of FluMist or any intranasal live attenuated influenza vaccine
- Previous enrollment in an H2N2 influenza vaccine trial or in any study of an avian influenza vaccine
- Seropositive to the H2N2 influenza A virus (serum HAI titer >1:8)
- Positive urine drug toxicology test indicating narcotic use and/or dependency as defined by the Drug Enforcement Agency
- Medical, occupational, or family problems as a result of alcohol or illicit drug use within the 12 months prior to study entry
- Any condition that, in the opinion of the investigator, would interfere with the study
- History of anaphylaxis
- Allergy to oseltamivir as determined by subject report
- Current diagnosis of asthma or reactive airway disease within 2 years prior to study entry
- History of Guillain-Barre Syndrome
- HIV-1-infected
- Hepatitis C-infected
- Positive hepatitis B virus surface antigen
- Known immunodeficiency syndrome
- Use of corticosteroids (excluding topical preparations) or immunosuppressive drugs within 30 days prior to study entry
- Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to study entry
- History of a surgical splenectomy
- Receipt of blood or blood-derived products (including immunoglobulin) within 6 months prior to study entry
- Current smoker unwilling to stop smoking for the duration of the study. More information on this criterion can be found in the protocol.
- Travel to the Southern Hemisphere within 14 days prior to study entry
- Travel on a cruise ship within 14 days prior to study entry
- Direct contact with live poultry within the 14 days prior to the study or after study completion.
- Receipt of another investigational vaccine or drug within 30 days prior to study entry
- Allergy to eggs or egg products
- Pregnant or breastfeeding
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: 1
Os participantes receberão 2 doses de vacina com 4 a 8 semanas (28-62 dias) de intervalo
|
Approximately 0.2 ml of 10^7 TCID50 doses of vaccine administered intranasally
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Quantidade de vírus da vacina derramado por cada participante
Prazo: Ao longo do estudo
|
Ao longo do estudo
|
|
Frequência de eventos de reatogenicidade relacionados à vacina e outros eventos adversos
Prazo: Ao longo do estudo
|
Ao longo do estudo
|
|
Quantidade de anticorpos séricos e de lavagem nasal induzidos pela vacina
Prazo: Ao longo do estudo
|
Ao longo do estudo
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Estabilidade fenotípica da disseminação do vírus da vacina
Prazo: Ao longo do estudo
|
Ao longo do estudo
|
|
Determinar se a imunogenicidade é aumentada por uma segunda dose de vacina e se a primeira dose de vacina restringe a replicação da segunda dose
Prazo: Ao longo do estudo
|
Ao longo do estudo
|
|
Number of participants infected with the H2N2 1960 AA ca recombinant vaccine
Prazo: Throughout study
|
Throughout study
|
|
T-cell mediated and innate immune responses against the H2N2 1960 AA ca recombinant vaccine
Prazo: Throughout study
|
Throughout study
|
Colaboradores e Investigadores
Colaboradores
Publicações e links úteis
Publicações Gerais
- Eichelberger M, Golding H, Hess M, Weir J, Subbarao K, Luke CJ, Friede M, Wood D. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine. 2008 Aug 12;26(34):4299-303. doi: 10.1016/j.vaccine.2008.06.012. Epub 2008 Jun 26.
- Hampson AW. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann Acad Med Singap. 2008 Jun;37(6):510-7.
- Wright PF. Vaccine preparedness--are we ready for the next influenza pandemic? N Engl J Med. 2008 Jun 12;358(24):2540-3. doi: 10.1056/NEJMp0803650. No abstract available.
Datas de registro do estudo
Datas Principais do Estudo
Conclusão Primária (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CIR 247
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .